AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04551664
Drug: Best medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
Trial: NCT02499120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Trial: NCT01827592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02810275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule received 1 tablet, taking in the morning, during four weeks
Trial: NCT01429298
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attending administers IV opioid of his choosing
Trial: NCT01305707
Drug: PHARMACOTHERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
Trial: NCT02058589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Trial: NCT01949142
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated single, intratympanic injection
Trial: NCT01900847
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline of same volume as appropriate weight based dose of ketamine
Trial: NCT00814723
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg MR, 12 weeks
Trial: NCT00814723
Drug: Fluvastatin plus ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluvastatin 80 mg MR plus ezetimibe 10 mg
Trial: NCT01353391
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
Trial: NCT00003522
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01307878
Drug: chemotherapy ± targeted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
Trial: NCT02905045
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02905045
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04959409
Drug: Topical analgesia (EMLA or AMETOP)
RxNorm normalized name: ANALGESIC TOP GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
Trial: NCT02872233
Drug: BAY 987519
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Trial: NCT02872233
Drug: SPF 15 Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Trial: NCT00734708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT01504139
Drug: hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
Trial: NCT01504139
Drug: hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
Trial: NCT01504139
Drug: vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase
RxNorm normalized name: ESTRADIOL/PROGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
Trial: NCT04651491
Drug: Kagocel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days.
Trial: NCT03478462
Drug: CLR 131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Trial: NCT03679143
Drug: Placebo 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
Trial: NCT03679143
Drug: ZSP1273 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets administered orally once daily under fasted condition
Trial: NCT03679143
Drug: Placebo 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Trial: NCT03679143
Drug: ZSP1273 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets administered orally once daily in the fasting state
Trial: NCT03679143
Drug: Placebo 400 mg
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
Trial: NCT03679143
Drug: ZSP1273 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets administered orally once daily under fasted condition
Trial: NCT03679143
Drug: Placebo 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Trial: NCT03679143
Drug: ZSP1273 900 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets administered orally once daily in the fasting state
Trial: NCT03679143
Drug: Placebo 900 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Trial: NCT03679143
Drug: ZSP1273 1200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets administered orally once daily in the fasting state
Trial: NCT03679143
Drug: Placebo 1200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
Trial: NCT03679143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
Trial: NCT03679143
Drug: ZSP1273 Median Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Trial: NCT03679143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Trial: NCT01718587
Drug: antiviral therapy (lamivudine, other antiviral drugs)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
Trial: NCT01666912
Drug: Contraceptive implant
RxNorm normalized name: Implanon Contraceptive Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00412932
Drug: Olmesartan medoxomil/hydrochlorothiazide
RxNorm normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01877668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
Trial: NCT00176657
Drug: HEMOBAG Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04485663
Drug: ALG-010133
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of ALG-010133
Trial: NCT04485663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of Placebo
Trial: NCT03190681
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ingestion of 3 tablets in a single-dose
Trial: NCT00002657
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650 mg/m\^2
Trial: NCT00002657
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2
Trial: NCT02090283
Drug: SD-101 dermal cream (6%)
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Trial: NCT03320265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly treatment for 3 months (4 administrations)
Trial: NCT01637714
Drug: Multi-strain probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water
Trial: NCT01637714
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water
Trial: NCT00003007
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002657
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 120 mg/m\^2
Trial: NCT03592836
Drug: Loop Diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of diuretics
Trial: NCT01455584
Drug: HM781-36B tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q1X28D/4W for HM781-36B tablets
Trial: NCT02258659
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02237989
Drug: paracetamol+native collagen type 2
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol (1500 mg) + native collagen type 2 (10mg)
Trial: NCT03029455
Drug: VX-659 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03029455
Drug: Triple Combination (TC) Matching Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04724785
Drug: regimen change
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
Trial: NCT00551174
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Trial: NCT00551174
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Trial: NCT01534416
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
Trial: NCT00004057
Drug: L-778,123
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00158262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching propranolol short-acting or long-acting capsule
Trial: NCT01808261
Drug: GSK249320 100/mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
Trial: NCT01223768
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice per day
Trial: NCT02204345
Drug: RO5479599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
Trial: NCT00613379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO, one IV dose (N=10)
Trial: NCT02354092
Drug: Preprocedural pain control
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg Ibuprofen taken before dilator placement
Trial: NCT02646319
Drug: Nanoparticle Albumin-Bound Rapamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02580253
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin,Fluorouracil
Trial: NCT04000126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml 0,9% NaCl iv 10min before intubation
Trial: NCT03295240
Drug: BR-I (bendamustine, rituximab, ibrutinib)
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
Trial: NCT03295240
Drug: VEN (Venetoclax)
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
Trial: NCT03247088
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05285787
Drug: EPN-701 (Oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7
Trial: NCT00007995
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02601222
Drug: Runzao zhiyang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Trial: NCT02601222
Drug: Urea cream
RxNorm normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Trial: NCT04265261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral placebo matched to RG7774
Trial: NCT04265261
Drug: RG7774
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral RG7774
Trial: NCT02182986
Drug: Immunosuppressive Drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
Trial: NCT01681953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions weekly
Trial: NCT01084148
Drug: V0034CR01B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01084148
Drug: V0034CR01B vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02757352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00497146
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT01736735
Drug: CLP
RxNorm normalized name: Endopeptidase Clp
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01736735
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02155309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00424593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every day (QD), by mouth (PO), 13 weeks
Trial: NCT00568737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT00572455
Drug: PF-04217329 - Lowest Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - Middle Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - High Middle Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - High Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-4217329 - Highest Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - Middle Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - High Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - Middle Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT00572455
Drug: PF-04217329 - High Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
Trial: NCT02824224
Drug: Placebo (for Tamoxifen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the tamoxifen 10mg tablet